menu
    • menu

    Company profile for Orlance

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orlance, headquartered in Seattle, WA, is actively developing its MACH-1® platform with the aim of delivering nucleic acid vaccines and related therapies without the constraints of cold chain requirements. The company has utilized $9.6 million in NIH SBIR funding to advance the MACH-1 platform, which enables the intradermal delivery of stable, powdered vaccines in a needle-free manner. By leveraging innovative technology, Orl...
    Orlance, headquartered in Seattle, WA, is actively developing its MACH-1® platform with the aim of delivering nucleic acid vaccines and related therapies without the constraints of cold chain requirements. The company has utilized $9.6 million in NIH SBIR funding to advance the MACH-1 platform, which enables the intradermal delivery of stable, powdered vaccines in a needle-free manner. By leveraging innovative technology, Orlance seeks to overcome logistical challenges associated with vaccine distribution and administration, contributing to improved accessibility and efficacy in the field of nucleic acid vaccines.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OrlanceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    401 Terry Ave N, Seattle, WA 98109, United States
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://orlance.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orlance Awarded 3.3M NIH Grant For MACH-1 Influenza Vaccine
    Orlance Awarded 3.3M NIH Grant For MACH-1 Influenza Vaccine

    10 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orlance-inc-awarded-3-3m-nih-sbir-grant-for-developing-mach-1-enhanced-seasonal-influenza-vaccine-302272442.html

    PR NEWSWIRE
    10 Oct 2024
    Share Share
    Orlance Collaborates On MACH-1 System Development
    Orlance Collaborates On MACH-1 System Development

    16 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/864294/orlance-announces-strategic-collaboration-with-product-creation-studio-for-the-development-of-the-mach-1-system

    ACCESSWIRE
    16 May 2024
    Share Share
    Orlance Awarded $3M NIH SBIR Grant for Advancing MACH-1 Needle-Free Vaccine
    Orlance Awarded $3M NIH SBIR Grant for Advancing MACH-1 Needle-Free Vaccine

    28 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orlance-inc-awarded-pivotal-3m-nih-sbir-grant-for-advancing-mach-1-needle-free-powdered-universal-influenza-vaccine-to-the-clinic-301999608.html

    PR NEWSWIRE
    28 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search